Research and Markets: Life Science February 2015 Issue - US President's Science Budget, Pfizer's Acquisition of Hospira, China's Redefined Foreign Investment Law, and President Obama's Precision Medicine Initiative

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/k73qhv/vital_signs_the) has announced the addition of the "Vital Signs - The Analyst's Perspective - February 2015 Issue" report to their offering.

This issue of Vital Signs, released on March 2, 2015, discusses the US President's science budget, Pfizer's acquisition of Hospira, China's redefined Foreign Investment Law, and President Obama's Precision Medicine Initiative.

The president's fiscal year (FY) 2016 budget request to Congress released in early February proposes an estimated $145.3 billion in total R&D funding (i.e., defense and non-defense), roughly a 6.4% increase in R&D spending from FY 2015 without factoring in inflation, according to the American Association for the Advancement of Science (AAAS). For scientific research funding, the National Institutes of Health (NIH), National Science Foundation (NSF), Department of Energy's (DOE) Office of Science, and U.S. Department of Agriculture's (USDA) Agriculture and Food Research Initiative will all receive increases above the estimated inflation level of 1.6%.

Under the budget, NIH would receive $31.3 billion, a $1 billion increase over FY 2015 levels providing a slim, but positive increase above inflation levels. The NSF's budget would increase 5.2% to $7.7 billion. The DOE's Office of Science would increase 5.4%, with the real winner the Office of Energy with a 28.7% increase directed mostly at the Energy Efficiency and Renewable Energy, and Electricity Delivery and Energy Reliability programs.

USDA's Agriculture and Food Research Initiative, a peer-reviewed competitive research program, would increase a hefty 40%. Below, AAAS illustrates the FY 2016 budget winners and losers in R&D funding, adjusted for 1.6% inflation.

Key Topics Covered:

1. First Look at President's Science Budget

2. Pfizer Acquires Hospira: An Expensive Investment for a Dud?

3. China Redefines the Foreign Investment Law

4. FACT SHEET: President Obama's Precision Medicine Initiative

For more information visit http://www.researchandmarkets.com/research/k73qhv/vital_signs_the

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716